John Maraganore makes a bold promise ahead of #JPM21 — aim­ing to take Al­ny­lam in­to the ranks of biotech's best

Al­ny­lam CEO John Maraganore is a big fan of five-year plans, and with JPM21 kick­ing off this week, he re­vealed his com­pa­ny’s newest am­bi­tious goal — be­come a “top 5 biotech” by 2025.

The ob­jec­tive is one of many Maraganore out­lined in his strat­e­gy for the next five years, which the Cam­bridge, MA-based com­pa­ny an­nounced Sun­day. Among the oth­er goals, of which not-so-co­in­ci­den­tal­ly there are five, he hopes to:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER